Regions Financial Corporation
—- Market cap
- $25.92B
- Debt
- +$4.88B
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 84% equity / 16% debt
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: RF stock price near parity vs GSK $30.43 current versus $30.06 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at GSK's multiple
Implied fair value · at RF's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Expensive
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: RF FY 2025 (ended Dec 31, 2025) · GSK FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 84% equity / 16% debt
Capital structure 71% equity / 29% debt · EV / Revenue 3.71x · EV / EBITDA 19.25x
GSK carries the larger enterprise value at $163.78B against $30.81B; GSK trades on the lower EV / Revenue multiple (3.71x vs 4.36x); RF on the lower EV / EBITDA (6.30x vs 19.25x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Regions Financial Corporation · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
GSK plc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.26x
—
Net debt / EBITDA
Leverage against operating earnings
—
6.59x
Cash and equivalents
Liquid reserves on the balance sheet
—
$3.40B
Total debt
Interest-bearing obligations outstanding
$4.88B
$44.87B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
JPMorgan Chase & Co.
RF vs JPM
Bank of America Corporation
RF vs BAC
Wells Fargo & Company
RF vs WFC
Citigroup Inc.
RF vs C
The Goldman Sachs Group, Inc.
RF vs GS
Morgan Stanley
RF vs MS
PFIZER INC
RF vs PFE
ELI LILLY & Co
RF vs LLY
BRISTOL MYERS SQUIBB CO
RF vs BMY
JOHNSON & JOHNSON
RF vs JNJ
AbbVie Inc.
RF vs ABBV
AMGEN INC
RF vs AMGN
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.